{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T02:12:28Z","timestamp":1774491148690,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04864-2","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T01:59:06Z","timestamp":1768960746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma concentrations of doxorubicin and cyclophosphamide during anthracycline-based chemotherapy in a pregnant breast cancer patient: evaluation of gestational changes"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0504-8930","authenticated-orcid":false,"given":"Sohei","family":"Ohshima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9162-5405","authenticated-orcid":false,"given":"Takuya","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8982-2312","authenticated-orcid":false,"given":"Hideaki","family":"Yashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0033-9028","authenticated-orcid":false,"given":"Yuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8229-0392","authenticated-orcid":false,"given":"Aoi","family":"Urano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9773-8821","authenticated-orcid":false,"given":"Tomoko","family":"Hirakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2932-7578","authenticated-orcid":false,"given":"Sayaka","family":"Obayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-391X","authenticated-orcid":false,"given":"Takaaki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3746-0232","authenticated-orcid":false,"given":"Koujirou","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"4864_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/IGC.0000000000000904","volume":"27","author":"F Parazzini","year":"2017","unstructured":"Parazzini F, Franchi M, Tavani A et al (2017) Frequency of pregnancy related cancer: A population based linkage study in Lombardy, Italy. Int J Gynecol Cancer 27:613\u2013619. https:\/\/doi.org\/10.1097\/IGC.0000000000000904","journal-title":"Int J Gynecol Cancer"},{"key":"4864_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/cncr.21610","volume":"106","author":"S Loibl","year":"2006","unstructured":"Loibl S, von Minckwitz G, Gwyn K et al (2006) Breast carcinoma during pregnancy: international recommendations from an expert meeting. Cancer 106:237\u2013246. https:\/\/doi.org\/10.1002\/cncr.21610","journal-title":"Cancer"},{"key":"4864_CR3","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00261-023-03824-1","volume":"48","author":"S Fazeli","year":"2023","unstructured":"Fazeli S, Sakala M, Rakow-Penner R, Ojeda-Fournier H (2023) Cancer in pregnancy: breast cancer. Abdom Radiol (NY) 48:1645\u20131662. https:\/\/doi.org\/10.1007\/s00261-023-03824-1","journal-title":"Abdom Radiol (NY)"},{"key":"4864_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.6004\/jnccn.2025.0053","volume":"23","author":"WJ Gradishar","year":"2025","unstructured":"Gradishar WJ, Moran MS, Abraham J et al (2025) NCCN guidelines\u00ae insights: breast cancer, version 5.2025: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 23:426\u2013436. https:\/\/doi.org\/10.6004\/jnccn.2025.0053","journal-title":"J Natl Compr Canc Netw"},{"key":"4864_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/17425255.2024.2420195","volume":"21","author":"P Dodeja","year":"2025","unstructured":"Dodeja P, Chaphekar N, Caritis SN, Venkataramanan R (2025) Optimizing drug therapy during pregnancy: a spotlight on population pharmacokinetic modeling. Expert Opin Drug Metab Toxicol 21:143\u2013160. https:\/\/doi.org\/10.1080\/17425255.2024.2420195","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4864_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002160","volume":"13","author":"G Pariente","year":"2016","unstructured":"Pariente G, Leibson T, Carls A et al (2016) Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med 13:e1002160. https:\/\/doi.org\/10.1371\/journal.pmed.1002160","journal-title":"PLoS Med"},{"key":"4864_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10928-020-09677-1","volume":"47","author":"JM Kazma","year":"2020","unstructured":"Kazma JM, van den Anker J, Allegaert K et al (2020) Anatomical and physiological alterations of pregnancy. J Pharmacokinet Pharmacodyn 47:271\u2013285. https:\/\/doi.org\/10.1007\/s10928-020-09677-1","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4864_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1124\/dmd.120.000067","volume":"48","author":"O Anoshchenko","year":"2020","unstructured":"Anoshchenko O, Prasad B, Neradugomma NK et al (2020) Gestational age-dependent abundance of human placental transporters as determined by quantitative targeted proteomics. Drug Metab Dispos 48:735\u2013741. https:\/\/doi.org\/10.1124\/dmd.120.000067","journal-title":"Drug Metab Dispos"},{"key":"4864_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/clpt.2008.1","volume":"84","author":"MF Hebert","year":"2008","unstructured":"Hebert MF, Easterling TR, Kirby B et al (2008) Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther 84:248\u2013253. https:\/\/doi.org\/10.1038\/clpt.2008.1","journal-title":"Clin Pharmacol Ther"},{"key":"4864_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/cncr.22081","volume":"107","author":"KME Hahn","year":"2006","unstructured":"Hahn KME, Johnson PH, Gordon N et al (2006) Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 107:1219\u20131226. https:\/\/doi.org\/10.1002\/cncr.22081","journal-title":"Cancer"},{"key":"4864_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S1470-2045(04)01466-4","volume":"5","author":"E Cardonick","year":"2004","unstructured":"Cardonick E, Iacobucci A (2004) Use of chemotherapy during human pregnancy. Lancet Oncol 5:283\u2013291. https:\/\/doi.org\/10.1016\/S1470-2045(04)01466-4","journal-title":"Lancet Oncol"},{"key":"4864_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0500-0","volume":"16","author":"RK Murthy","year":"2014","unstructured":"Murthy RK, Theriault RL, Barnett CM et al (2014) Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res 16:500. https:\/\/doi.org\/10.1186\/s13058-014-0500-0","journal-title":"Breast Cancer Res"},{"key":"4864_CR13","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S1470-2045(12)70261-9","volume":"13","author":"S Loibl","year":"2012","unstructured":"Loibl S, Han SN, von Minckwitz G et al (2012) Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol 13:887\u2013896. https:\/\/doi.org\/10.1016\/S1470-2045(12)70261-9","journal-title":"Lancet Oncol"},{"key":"4864_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003088-198815010-00002","volume":"15","author":"PA Speth","year":"1988","unstructured":"Speth PA, van Hoesel QG, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15:15\u201331. https:\/\/doi.org\/10.2165\/00003088-198815010-00002","journal-title":"Clin Pharmacokinet"},{"key":"4864_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ajco.13776","volume":"19","author":"J Methaneethorn","year":"2023","unstructured":"Methaneethorn J, Tengcharoen K, Leelakanok N, AlEjielat R (2023) Population pharmacokinetics of doxorubicin: a systematic review. Asia Pac J Clin Oncol 19:9\u201326. https:\/\/doi.org\/10.1111\/ajco.13776","journal-title":"Asia Pac J Clin Oncol"},{"key":"4864_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215436","volume":"14","author":"AA Bagdasaryan","year":"2022","unstructured":"Bagdasaryan AA, Chubarev VN, Smolyarchuk EA et al (2022) Pharmacogenetics of drug metabolism: the role of gene polymorphism in the regulation of doxorubicin safety and efficacy. Cancers (Basel) 14:5436. https:\/\/doi.org\/10.3390\/cancers14215436","journal-title":"Cancers (Basel)"},{"key":"4864_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00280-014-2406-z","volume":"73","author":"RJ Ryu","year":"2014","unstructured":"Ryu RJ, Eyal S, Kaplan HG et al (2014) Pharmacokinetics of doxorubicin in pregnant women. Cancer Chemother Pharmacol 73:789\u2013797. https:\/\/doi.org\/10.1007\/s00280-014-2406-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"4864_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","volume":"44","author":"GD Anderson","year":"2005","unstructured":"Anderson GD (2005) Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach: A mechanistic-based approach. Clin Pharmacokinet 44:989\u20131008. https:\/\/doi.org\/10.2165\/00003088-200544100-00001","journal-title":"Clin Pharmacokinet"},{"key":"4864_CR19","doi-asserted-by":"publisher","first-page":"151221","DOI":"10.1016\/j.semperi.2020.151221","volume":"44","author":"EA Pinheiro","year":"2020","unstructured":"Pinheiro EA, Stika CS (2020) Drugs in pregnancy: pharmacologic and physiologic changes that affect clinical care. Semin Perinatol 44:151221. https:\/\/doi.org\/10.1016\/j.semperi.2020.151221","journal-title":"Semin Perinatol"},{"key":"4864_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s10147-016-1036-3","volume":"22","author":"A Odelia","year":"2017","unstructured":"Odelia A, Erel J, Chava P et al (2017) Continuing dilemmas in the management of lymphoma during pregnancy: review of a 10-point case-based questionnaire. Int J Clin Oncol 22:190\u2013199. https:\/\/doi.org\/10.1007\/s10147-016-1036-3","journal-title":"Int J Clin Oncol"},{"key":"4864_CR21","doi-asserted-by":"publisher","unstructured":"Du BOISD (1916) Clinical calorimetry: tenth paper a formula to estimate the approximate surface area if height and weight be known. Arch Intern Med (Chic) XVII 863. https:\/\/doi.org\/10.1001\/archinte.1916.00080130010002","DOI":"10.1001\/archinte.1916.00080130010002"},{"key":"4864_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-0802-4","volume":"4","author":"A Blaes","year":"2015","unstructured":"Blaes A, Duprez D, Defor T et al (2015) Angiotensin converting enzyme inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. Springerplus 4:32. https:\/\/doi.org\/10.1186\/s40064-015-0802-4","journal-title":"Springerplus"},{"key":"4864_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4864_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ramb.2012.10.003","volume":"59","author":"DLM Monteiro","year":"2013","unstructured":"Monteiro DLM, Trajano AJB, Menezes DCS et al (2013) C\u00e2ncer de mama na gravidez e quimioterapia: revis\u00e3o sistem\u00e1tica. Rev Assoc Med Bras 59:174\u2013180. https:\/\/doi.org\/10.1016\/j.ramb.2012.10.003","journal-title":"Rev Assoc Med Bras"},{"key":"4864_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bcp.12989","volume":"82","author":"S Liang","year":"2016","unstructured":"Liang S, Brundage RC, Jacobson PA et al (2016) Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer. Br J Clin Pharmacol 82:773\u2013783. https:\/\/doi.org\/10.1111\/bcp.12989","journal-title":"Br J Clin Pharmacol"},{"key":"4864_CR26","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/annonc\/mdu140","volume":"25","author":"JGC van Hasselt","year":"2014","unstructured":"van Hasselt JGC, van Calsteren K, Heyns L et al (2014) Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann Oncol 25:2059\u20132065. https:\/\/doi.org\/10.1093\/annonc\/mdu140","journal-title":"Ann Oncol"},{"key":"4864_CR27","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1124\/mol.107.043851","volume":"74","author":"H Zhang","year":"2008","unstructured":"Zhang H, Wu X, Wang H et al (2008) Effect of pregnancy on cytochrome P450 3a and P-glycoprotein expression and activity in the mouse: mechanisms, tissue specificity, and time course. Mol Pharmacol 74:714\u2013723. https:\/\/doi.org\/10.1124\/mol.107.043851","journal-title":"Mol Pharmacol"},{"key":"4864_CR28","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1021\/mp900077q","volume":"6","author":"LD Coles","year":"2009","unstructured":"Coles LD, Lee IJ, Voulalas PJ, Eddington ND (2009) Estradiol and progesterone-mediated regulation of P-gp in P-gp overexpressing cells (NCI-ADR-RES) and placental cells (JAR). Mol Pharm 6:1816\u20131825. https:\/\/doi.org\/10.1021\/mp900077q","journal-title":"Mol Pharm"},{"issue":"5","key":"4864_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/QAI.0b013e318186edd0","volume":"49","author":"M Mirochnick","year":"2008","unstructured":"Mirochnick M, Best BM, Stek AM et al (2008) Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 49(5):485\u201391. https:\/\/doi.org\/10.1097\/QAI.0b013e318186edd0","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"15","key":"4864_CR30","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1097\/01.aids.0000247114.43714.90","volume":"20","author":"AM Stek","year":"2006","unstructured":"Stek AM, Mirochnick M, Capparelli E et al (2006) Reduced lopinavir exposure during pregnancy. AIDS 20(15):1931\u20139. https:\/\/doi.org\/10.1097\/01.aids.0000247114.43714.90","journal-title":"AIDS"},{"issue":"15","key":"4864_CR31","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2165\/00003088-200443150-00002","volume":"43","author":"M Mirochnick","year":"2004","unstructured":"Mirochnick M, Capparelli E (2004) Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 43(15):1071\u20131087. https:\/\/doi.org\/10.2165\/00003088-200443150-00002","journal-title":"Clin Pharmacokinet"},{"key":"4864_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-356","volume":"9","author":"KJ Patel","year":"2009","unstructured":"Patel KJ, Tannock IF (2009) The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer 9:356. https:\/\/doi.org\/10.1186\/1471-2407-9-356","journal-title":"BMC Cancer"},{"key":"4864_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00406","volume":"11","author":"JH Ahmed","year":"2020","unstructured":"Ahmed JH, Makonnen E, Bisaso RK et al (2020) Population pharmacokinetic, pharmacogenetic, and pharmacodynamic analysis of cyclophosphamide in Ethiopian breast cancer patients. Front Pharmacol 11:406. https:\/\/doi.org\/10.3389\/fphar.2020.00406","journal-title":"Front Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04864-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04864-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04864-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T01:59:07Z","timestamp":1768960747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04864-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4864"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04864-2","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"12"}}